Bicycle Therapeutics plc

Bicycle Therapeutics plc 在 2026年7月30日 公布了什么

截至 2026年6月30日 的季度，与去年同季度相比。

这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。

对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。

业绩电话会

暂无 Bicycle Therapeutics plc 的业绩电话会文字记录。

管理层说了什么

“We are pleased with the progress we made during the second quarter. Our financial discipline with refined focus on nuzefatide pevedotin and our next-generation Bicycle conjugate pipeline, including Bicycle ® Radioconjugates (BRC ® ), leaves us well capitalized to pursue our mission to help patients to not only live longer, but also live well,”

逐字引自公告，且只在文件将其归于具名人士时才展示。

股价作何反应

公告在收盘后或开盘前发布，因此这里的变动是随后的那个交易日。

Bicycle Therapeutics plc 做什么

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle ® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle ® Drug Conjugate (BDC ® ) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle ® Radioconjugates (BRC ® ) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC ® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle ® technology to develop therapies for diseases in additional therapeutic areas. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Mass.

公司自己的描述，取自公告末尾。